Group 1 - The core viewpoint of the article highlights the surge in Hong Kong stocks related to brain-computer interface (BCI) concepts, driven by OpenAI founder Sam Altman's comments on the rapid adoption of ChatGPT and plans to enter the consumer hardware, BCI, and social media sectors [1] - Heartway Medical (心玮医疗) saw a significant increase of 12.5%, reaching a new high, while other companies like Brainhole Technology (脑洞科技) and Nanjing Panda Electronics (南京熊猫电子) also experienced gains [1] - Analysts suggest that OpenAI's entry into the BCI sector will boost technological confidence and capital interest in the industry, particularly benefiting computation-dependent and AI-integrated BCI companies [1] Group 2 - The article emphasizes that while the entry of major players like OpenAI is promising, the maturity of the BCI industry will require time, and investors should focus on technological advancements rather than short-term speculation [1] - The stock performance of related companies includes Lenovo Group (联想集团) rising by 2.96%, Brainhole Technology (脑洞科技) increasing by 2.87%, Nanjing Panda Electronics (南京熊猫电子) up by 0.66%, and Brainstorm Aurora (脑动极光) gaining 0.54% [1]

Group 1 - The Ministry of Transport, Ministry of Finance, and Ministry of Natural Resources have issued a plan to complete the construction and renovation of 300,000 kilometers of rural roads by 2027, aiming to establish a convenient and efficient rural road network [1] - The plan includes implementing 300,000 kilometers of repair and maintenance projects, maintaining a good road condition rate of over 70%, and carrying out safety protection projects on 150,000 kilometers of roads [1] - The initiative aims to enhance rural transportation services and support the vision of a well-structured, high-quality rural transportation system by 2035 [1] Group 2 - U.S. stock markets saw an overall increase, with the Dow Jones rising by 81.38 points (0.19%) and the Nasdaq increasing by 252.87 points (1.21%) [2] - Notable stock movements included Apple rising by 5% due to anticipated investments in U.S. manufacturing, and McDonald's gaining over 3% following better-than-expected earnings [2] - Many popular Chinese concept stocks also saw gains, with Alibaba up over 3% and NIO increasing by over 2% [2] Group 3 - The State Grid reported a record high electricity load for three consecutive days, reaching a maximum load of 1.233 billion kilowatts, an increase of 53 million kilowatts compared to last year's peak [3] - The electricity load is expected to remain above 1.2 billion kilowatts, with a potential decrease anticipated due to upcoming rainfall and cooler temperatures [3] Group 4 - The Hong Kong Monetary Authority intervened in the currency market, buying HKD 8.439 billion after the Hong Kong dollar hit the weak end of its trading band [4] - This action is part of the linked exchange rate system, where the HKMA sells USD and buys HKD to stabilize the currency [4] Group 5 - The China Photovoltaic Industry Association is soliciting opinions on the draft amendment to the Price Law, focusing on price behavior norms and regulatory mechanisms [5] - This initiative aims to reflect the demands of the photovoltaic industry and gather feedback for potential modifications [5] Group 6 - Guangnan Group's subsidiary successfully acquired land use rights in Foshan for RMB 56.16 million, expanding its meat industry chain [6] Group 7 - Caocao Travel is exploring the tokenization of real-world assets and stablecoin payments through a strategic partnership with a licensed financial institution in Hong Kong [7][8] Group 8 - Lianzhong is integrating AI technology into traditional board games, collaborating with tech companies to enhance gaming experiences [9] Group 9 - China National Pharmaceutical Group's self-developed drug TQ05105 has been included in the breakthrough therapy designation program for chronic graft-versus-host disease treatment [10] Group 10 - China Nuclear Technology expects a mid-year profit increase of no less than 15% compared to the previous year [11] Group 11 - Hengrui Medicine's product received orphan drug designation from the FDA, which may provide regulatory advantages in the U.S. market [12] Group 12 - Huaxian Optoelectronics anticipates a significant profit increase of at least 600% for the first half of 2025 [13] Group 13 - New World Development expects a mid-year profit of no less than HKD 800 million, a substantial increase from the previous year's HKD 75.4 million [14] Group 14 - Xinwei Medical expects to achieve a net profit of at least RMB 40 million in the first half of 2025, marking a turnaround from losses [15] Group 15 - Zhiyu Technology anticipates a mid-year profit increase of approximately 108.9% to 126.7% [16] Group 16 - Ningmeng Media expects to achieve a net profit of approximately RMB 10 million to 12 million in the first half of 2025, reversing previous losses [17] Group 17 - Weixin Jinke anticipates a significant profit increase of no less than RMB 200 million for the first half of 2025, reflecting a growth of at least 65% [18] Group 18 - Uni-President China reported a 33.24% increase in shareholder profit to RMB 1.287 billion for the mid-year period [19] Group 19 - BeiGene reported a net profit of USD 94.32 million for the second quarter, marking a turnaround from a loss of USD 120 million in the previous year [20] Group 20 - Maifushi expects to achieve a net profit of approximately RMB 31.8 million to 41 million in the first half of 2025, reversing a significant loss from the previous year [21]

Performance Highlights - BeiGene (06160.HK) reported a revenue of 17.518 billion yuan for the first half of the year, a year-on-year increase of 46%; product revenue was 17.36 billion yuan, up 45.8%; net profit was 450 million yuan, turning from loss to profit [2] - Uni-President China (00220.HK) achieved approximately 17.087 billion yuan in revenue for the first half, a year-on-year increase of 10.6%; net profit was about 1.287 billion yuan, up 33.2% [2] - Zhiyu City Technology (09911.HK) announced a positive profit forecast, expecting mid-term revenue of approximately 3.135 to 3.215 billion yuan, a year-on-year increase of about 38.0% to 41.5%; net profit is expected to be around 470 to 510 million yuan, a year-on-year growth of approximately 108.9% to 126.7% [2] Earnings Forecasts - New World Development Company (00086.HK) expects mid-term net profit to increase to no less than 800 million HKD year-on-year [3] - Weizhi Jinkou (02003.HK) anticipates mid-term net profit exceeding 200 million HKD, a significant increase year-on-year [3] - Wing Chan Industrial (01596.HK) forecasts mid-term net profit of approximately 48.7 million HKD, turning from loss to profit [3] - Huaxian Optoelectronics (00334.HK) expects mid-term net profit to exceed 48.8 million HKD, a year-on-year increase of over 600% [3] - Maifushi (02556.HK) predicts mid-term net profit of approximately 31.8 to 41 million HKD, turning from loss to profit [4] - Xinwei Medical-B (06609.HK) expects mid-term net profit to exceed 40 million HKD, turning from loss to profit [5] - China Nuclear Technology (00611.HK) anticipates mid-term net profit growth of over 15% [6] Earnings Warnings - Hongxing Printing Group (00450.HK) expects mid-term net loss of approximately 49 million HKD, a significant increase year-on-year [7] - Zhongyu Land (01224.HK) forecasts mid-term net loss of approximately 40 million HKD, turning from profit to loss [7] - Beihai Group (00701.HK) anticipates mid-term net loss of 36 to 40 million HKD [8] Real Estate Sales Data - China Overseas Development (00688.HK) reported cumulative contract property sales of approximately 132 billion yuan for the first seven months, a year-on-year decrease of 18.3% [9] - Yuexiu Property (00123.HK) achieved cumulative contract sales of approximately 67.506 billion yuan for the first seven months, a year-on-year increase of about 11.7% [9] - Poly Property Group (00119.HK) reported contract sales of approximately 29.5 billion yuan for the first seven months, a year-on-year decrease of 13.49% [10] - China Overseas Hongyang Group (00081.HK) reported cumulative contract sales of 18.649 billion yuan for the first seven months, a year-on-year decrease of 12.2% [10] - Jindi Commercial Real Estate (00535.HK) reported cumulative contract sales of approximately 6.98 billion yuan for the first seven months, a year-on-year decrease of 37.37% [10] - Agile Group (03383.HK) reported pre-sale amount of approximately 5.69 billion yuan for the first seven months [11] - Hongyang Real Estate (01996.HK) reported cumulative contract sales of 3.208 billion yuan for the first seven months, a year-on-year decrease of 41.6% [12] - Zhengrong Real Estate (06158.HK) reported cumulative contract sales of approximately 2.701 billion yuan for the first seven months, a year-on-year decrease of 30.6% [12] - Jingrui Holdings (01862.HK) reported cumulative contract sales of approximately 571 million yuan for the first seven months, a year-on-year decrease of 52.54% [13] Company News - CITIC Securities (06030.HK) reported that its subsidiary, Huaxia Fund, achieved revenue of 4.258 billion yuan and net profit of 1.123 billion yuan in the first half, with assets under management totaling 285.1237 billion yuan [14] - Xinyi International (00732.HK) reported a cumulative operating revenue of approximately 9.566 billion HKD for the first seven months, a year-on-year decrease of about 5.3% [15] - Heng Rui Pharmaceutical (01276.HK) received orphan drug designation from the US FDA for its injection of Rikan Trastuzumab combined with Adebali for gastric cancer or gastroesophageal junction adenocarcinoma indications [15] - Fuhong Hanlin (02696.HK) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanlikang® for active renal glomerulonephritis in China [15] - China Biopharmaceutical (01177.HK) announced that its self-developed TQ05105 (JAK/ROCK inhibitor) has been included in the breakthrough therapy designation program for the treatment of chronic graft-versus-host disease [15] Buyback Activities - HSBC Holdings (00005.HK) repurchased approximately 1.65 billion HKD worth of about 1.714 million shares at a price of 95.8 to 96.75 HKD [16] - Hang Seng Bank (00011.HK) spent approximately 22.6347 million HKD to repurchase 200,000 shares at a price of 112.8 to 113.6 HKD [17] - Yum China (09987.HK) repurchased approximately 6.264 million HKD worth of 16,800 shares at a price of 369.8 to 376 HKD [17]

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of no less than RMB 40 million in the first half of 2025, marking a turnaround from loss to profit primarily due to increased sales of hemorrhagic stroke treatment devices and effective cost control measures [1] Group 1 - The increase in revenue is driven by the sales growth of newly launched hemorrhagic stroke treatment devices and acute ischemic stroke treatment devices [1] - Effective cost control measures have led to a decrease in overall expense ratio, contributing to improved profitability [1] - Changes in the research and development phase of projects have resulted in reduced R&D expenditures [1] - There has been an increase in fair value gains from financial assets measured at fair value through profit or loss [1]

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of no less than RMB 40 million in the first half of 2025, marking a turnaround from loss to profit primarily due to increased sales of newly launched hemorrhagic stroke treatment devices and effective cost control measures [1] Group 1 - The increase in revenue is driven by the sales growth of newly launched hemorrhagic stroke treatment devices and acute ischemic stroke treatment devices [1] - Effective cost control measures have led to a decrease in overall expense ratio, contributing to the company's profitability [1] - Changes in the research and development phase of projects have resulted in reduced R&D expenditures [1] - There has been an increase in fair value gains on financial assets measured at fair value through profit or loss [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） 承董事會命 上海心瑋醫療科技股份有限公司 正面盈利預告 補充公告 本公告由上海心瑋醫療科技股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)條 以及香港法例第571章證券及期貨條例第XIVA部項下的內幕消息條文（定義見 上市規則）刊發。 茲提述本公司日期為2025年7月29日的公告，內容有關（其中包括）本集團截至 2025年6月30日止六個月的正面盈利預告（「該公告」）。除非另行界定，否則本 公告所用詞彙與該公告所界定者具有相同涵義。 董事會謹此補充並知會股東及潛在投資者， ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 2. 股份分類 | 普通股 | 股份類別 | | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 非上巿股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 7,268,604 | RMB | | | 1 RMB | | 7,268,604 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 7,268,604 | RMB | | | 1 RMB | ...

（股份代號：6609） Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） 1. 請用正楷填上登記在股東名冊上之股東全名及地址。 2. 請填上以 閣下名義登記且與本代表委任表格有關的本公司股份數目。倘填上數目，則本代表委任表格將被視為僅與該等股份有關。倘未有填上數目，則代 表委任表格將被視為與以 閣下名義登記的所有本公司股份有關（不論獨自或聯名持有）。 3. 倘擬委任大會主席以外的人士為代表，請刪去「大會主席」字樣，並在空欄內填上擬委派代表的姓名及地址。凡有權出席大會及於會上投票的股東，均可委 派一名或多名代表（如其所持股份多於一股）出席大會並代其投票，惟倘委派一名以上的代表，則須指明每一名受委代表所代表的股份類別及數目。受委代 表毋須為本公司股東。本代表委任表格之每項更正，均須由簽署人簡簽示可。 4. 注意：倘 閣下擬投票贊成任何決議案，請在註明「贊成」欄內填上「✓」號或填上以 閣下名義登記的股份數目。倘 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容所產生或因依賴該等內 容而引致的任何損失承擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 2025年第二次臨時股東大會通告 茲通告上海心瑋醫療科技股份有限公司（「本公司」，連同其附屬公司統稱「本集團」） 謹訂於2025年8月29日（星期五）上午十時正假座中國上海市自由貿易試驗區臨港新片區 正博路356號8幢4層思脉德廳舉行2025年第二次臨時股東大會（「臨時股東大會」），藉以 審議及酌情通過以下決議案。除另有界定者外，本通告所用詞彙與本公司日期為2025 年8月1日的通函（「通函」）所界定者具有相同涵義。 普通決議案 1. 審議及批准根據組織章程細則、相關法律及法規，利用本公司資本儲備抵銷本公 司虧損人民幣575,0 ...

此乃要件 請即處理 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本通函全部或任何部分內容所產生或因依賴該等內 容而引致的任何損失承擔任何責任。 閣下如對本通函任何方面或將採取的行動有任何疑問，應諮詢 閣下之股票經紀或其他註冊證券交 易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓名下所有上海心瑋醫療科技股份有限公司股份，應立即將本通函交予買主或承 讓人，或經手買賣或轉讓的銀行、股票經紀或其他代理商，以便轉交買主或承讓人。 本通函僅作參考用途，並不構成收購、購買或認購任何本公司證券的邀請或要約。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） (1) 利用資本儲備抵銷虧損； 及 (2) 2025年第二次臨時股東大會通告 本封面頁所用詞彙與本通函所界定者具相同涵義。 董事會函件載於 ...